Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: Role of the Jun NH2-terminal kinase

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 285, Issue 5 54-5, 2003, Pages

  Frost, Robert A ^a   Nystrom, Gerald J ^a   Lang, Charles H ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Interleukin 1 ; Mitogen activated protein kinase; Skeletal muscle; Tumor necrosis factor

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYTOKINE; DEXAMETHASONE; ENZYME INHIBITOR; GLUCOCORTICOID; I KAPPA B; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; LYMPHOCYTE; MACROPHAGE; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 0142031629     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00164.2003     Document Type: Article

References (55)

1. Andersson U and Matsuda T. Human interleukin-6 and tumor necrosis factor-α production studied at a single-cell level. Eur J Immunol 19: 1157-1160, 1989.
2. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, Olivieri F, Giovagnetti S, Franceschi C, Guralnik JM, and Paolisso G. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 284: E481-E487, 2003.
3. Baumgarten G, Knuefermann P, Nozaki N, Sivasubramanian N, Mann DL, and Vallejo JG. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis 183: 1617-1624, 2001.
4. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, and Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681-13686, 2001.
5. Blanco-Bose WE, Yao CC, Kramer RH, and Blau HM. Purification of mouse primary myoblasts based on alpha 7 integrin expression. Exp Cell Res 265: 212-220, 2001.
6. 2-terminal kinase activity in human skeletal muscle. J Appl Physiol 87: 1668-1673, 1999.
7. Chen P, Li J, Barnes J, Kokkonen GC, Lee JC, and Liu Y. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 169: 6408-6416, 2002.
8. Cross JV, Deak JC, Rich EA, Qian Y, Lewis M, Parrott LA, Mochida K, Gustafson D, Vande Pol S, and Templeton DJ. Quinone reductase inhibitors block SAPK/JNK and NFκB pathways and potentiate apoptosis. J Biol Chem 274: 31150-31154, 1999.
9. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, and Fattori E. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 99: 643-650, 1997.
10. Dela F, Larsen JJ, Mikines KJ, Ploug T, Petersen LN, and Galbo H. Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training. Diabetes 44: 1010-1020, 1995.
11. Dendorfer U, Oettgen P, and Libermann TA. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 14: 4443-4454, 1994.
12. Eickelberg O, Pansky A, Mussmann R, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, and Roth M. Transforming growth factor-β1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J Biol Chem 274: 12933-12938, 1999.
13. Fan J, Char D, Bagby GJ, Gelato MC, and Lang CH. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol Regul Integr Comp Physiol 269: R1204-R1212, 1995.
14. Fernandez-Celemin L, Pasko N, Blomart V, and Thissen JP. Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-α. Am J Physiol Endocrinol Metab 283: E1279-E1290, 2002.
15. Filosto M, Tonin P, Vattemi G, Savio C, Rizzuto N, and Tomelleri G. Transcription factors c-Jun/activator protein-1 and nuclear factor-κB in oxidative stress response in mitochondrial diseases. Neuropathol Appl Neurobiol 29: 52-59, 2003.
16. Frost RA, Lang CH, and Gelato MC. Transient exposure of human myoblasts to tumor necrosis factor-α inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology 138: 4153-4159, 1997.
17. Frost RA, Nystrom GJ, and Lang CH. Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle. Am J Physiol Regul Integr Comp Physiol 283: R698-R709, 2002.
18. Frost RA, Nystrom GJ, and Lang CH. Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts. Endocrinology 143: 492-503, 2002.
19. Frost RA, Nystrom GJ, and Lang CH. Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1β: requirement of the mitogen-activated protein kinase pathway. Endocrinology 141: 3156-3164, 2000.
20. Frost RA, Nystrom GJ, and Lang CH. Tumor necrosis factor-α decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 144: 1770-1779, 2003.
21. Gallucci S, Provenzano C, Mazzarelli P, Scuderi F, and Bartoccioni E. Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol 10: 267-273, 1998.
22. Galvan V, Logvinova A, Sperandio S, Ichijo H, and Bredesen DE. IGF-IR signaling inhibits apoptosis signal-regulating kinase I (ASK1). J Biol Chem 28: 28, 2003.
23. Haddad JJ and Fahlman CS. Nuclear factor-κB-independent regulation of lipopolysaccharide-mediated interleukin-6 biosynthesis. Biochem Biophys Res Commun 291: 1045-1051, 2002.
24. Hagemann C, Patel R, and Blank JL. MEKK3 interacts with the PA28γ regulatory subunit of the proteasome. Biochem J 373: 71-79, 2003.
25. Jonsdottir IH, Schjerling P, Ostrowski K, Asp S, Richter EA, and Pedersen BK. Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles. J Physiol 528: 157-163, 2000.
26. Kami K and Senba E. Localization of leukemia inhibitory factor and interleukin-6 messenger ribonucleic acids in regenerating rat skeletal muscle. Muscle Nerve 21: 819-822, 1998.
27. Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK, and Neufer PD. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15: 2748-2750, 2001.
28. Kurek JB, Austin L, Cheema SS, Bartlett PF, and Murphy M. Upregulation of leukaemia inhibitory factor and interleukin-6 in transected sciatic nerve and muscle following denervation. Neuromuscul Disord 6: 105-114, 1996.
29. Lang CH, Silvis C, Deshpande N, Nystrom G, and Frost RA. Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor-α, interleukin-1B, -6, and high mobility group protein-1 in skeletal muscle. Shock 19: 538-546, 2003.
30. Luo G, Hershko DD, Robb BW, Wray CJ, and Hasselgren PO. IL-1β stimulates IL-6 production in cultured skeletal muscle cells through activation of MAP kinase signaling pathway and NF-κB. Am J Physiol Regul Integr Comp Physiol 284: R1249-R1254, 2003.
31. May LT, Torcia G, Cozzolino F, Ray A, Tatter SB, Santhanam U, Sehgal PB, and Stern D. Interleukin-6 gene expression in human endothelial cells: RNA start sites, multiple IL-6 proteins and inhibition of proliferation. Biochem Biophys Res Commun 159: 991-998, 1989.
32. Mazzarelli P, Scuderi F, Mistretta G, Provenzano C, and Bartoccioni E. Effect of transforming growth factor-β1 on interleukin-6 secretion in human myoblasts. J Neuroimmunol 87: 185-188, 1998.
33. Mazzeo RS, Donovan D, Fleshner M, Butterfield GE, Zamudio S, Wolfel EE, and Moore LG. Interleukin-6 response to exercise and high-altitude exposure: influence of α-adrenergic blockade. J Appl Physiol 91: 2143-2149, 2001.
34. Mc Gee MM, Campiani G, Ramunno A, Nacci V, Lawler M, Williams DC, and Zisterer DM. Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J Biol Chem 277: 18383-18389, 2002.
35. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, Volk HD, Holtmann H, Kollias G, and Gaestel M. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different posttranscriptional levels. J Biol Chem 277: 3065-3068, 2002.
36. Ostrowski K, Rohde T, Zacho M, Asp S, and Pedersen BK. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 508: 949-953, 1998.
37. Pedersen BK, Steensberg A, Keller P, Keller C, Fischer C, Hiscock N, Van Hall G, Plomgaard P, and Febbraio MA. Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects. Pflügers Arch 446: 9-16, 2003.
38. Penner CG, Gang G, Wray C, Fischer JE, and Hasselgren PO. The transcription factors NF-κB and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun 281: 1331-1336, 2001.
39. Pritts TA, Hungness ES, Hershko DD, Robb BW, Sun X, Luo GJ, Fischer JE, Wong HR, and Hasselgren PO. Proteasome inhibitors induce heat shock response and increase IL-6 expression in human intestinal epithelial cells. Am J Physiol Regul Integr Comp Physiol 282: R1016-R1026, 2002.
40. Ramadori G and Christ B. Cytokines and the hepatic acute-phase response. Semin Liver Dis 19: 141-155, 1999.
41. Remick DG, Bolgos GR, Siddiqui J, Shin J, and Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463-467, 2002.
42. Remick DG, Call DR, Ebong SJ, Newcomb DE, Nybom P, Nemzek JA, and Bolgos GE. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 29: 473-481, 2001.
43. Remick DG, Newcomb DE, Bolgos GL, and Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13: 110-116, 2000.
44. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, and Ward PA. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 170: 503-507, 2003.
45. Shin M, Yan C, and Boyd D. An inhibitor of c-jun amino terminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 1589: 311-316, 2002.
46. Smart DE, Vincent KJ, Arthur MJ, Eickelberg O, Castellazzi M, Mann J, and Mann DA. JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. J Biol Chem 276: 24414-24421, 2001.
47. Steensberg A, Toft AD, Schjerling P, Halkjaer-Kristensen J, and Pedersen BK. Plasma interleukin-6 during strenuous exercise: role of epinephrine. Am J Physiol Cell Physiol 281: C1001-C1004, 2001.
48. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, and Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268: E813-E819, 1995.
49. Svanberg E, Frost RA, Lang CH, Isgaard J, Jefferson LS, Kimball SR, and Vary TC. IGF-I/IGFBP-3 binary complex modulates sepsis-induced inhibition of protein synthesis in skeletal muscle. Am J Physiol Endocrinol Metab 279: E1145-E1158, 2000.
50. Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 6: D164-D174, 2001.
51. Vanhaesebroeck B and Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239-254, 1999.
52. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, and Harris TB. Relationship of interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 57: M326-M332, 2002.
53. Wang SW, Pawlowski J, Wathen ST, Kinney SD, Lichenstein HS, and Manthey CL. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm Res 48: 533-538, 1999.
54. Wu HM, Chi KH, and Lin WW. Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett 526: 101-105, 2002.
55. Yu XN, Komaki G, Sudo N, and Kubo C. Central and peripheral catecholamines regulate the exercise-induced elevation of plasma interleukin 6 in rats. Life Sci 69: 167-174, 2001.